Skip to main content

October 2015

 

 

academics

 

Clinical research courses

Job as Data Associate in World Health Organization

WHO is the directing and coordinating authority for health within the United Nations system. It is responsible for providing leadership on global health matters, shaping the health research agenda, setting norms and standards, articulating evidence-based policy options, providing technical support to countries and monitoring and assessing health trends.

Post: Data Associate

Work as Executive - Sterile Production in Piramal Healthcare

Piramal Enterprises Ltd. provides a world class integrated drug discovery services platform from our state-of-the-art research Centre in India. PDS's delivery model has a proven track record of providing a step change in the effectiveness of drug discovery for a range of global pharmaceuticals and biotechnology companies operating at the forefront of drug discovery.

- 50% of ALF cases happen due to Hepatitis A&E, unavailability of clean potable water

- ALF mortality has come down to 20 % from 80 % in last 10 years due to advancement in liver intensive care and liver transplantation of ALF patients.

(NewsVoir); The expert team of Department of Hepatology at Global Hospitals - one of the fastest growing chains of multi-super speciality, multi-organ transplant and quaternary care hospitals in Mumbai, shared their experience in treating and managing Acute Liver Failure patients medically and through transplantation.

(adsbygoogle = window.adsbygoogle || []).push({});

Boehringer Ingelheim today announced the presentation of several new post-hoc analyses from the TONADO® 1&2 and OTEMTO® 1&2 studies at the American College of CHEST Physicians Annual Meeting in Montreal. One analysis showed significant lung function improvement, as measured by FEV1 AUC0–3, with once daily Spiolto® Respimat® in COPD patients* across a range of age groups, including those over 65 years of age.1 In addition, a second analysis indicated that Spiolto® Respimat® reduces the frequency of night-time rescue medication use, as measured by puffs needed per night2 and these reductions were sustained for up to 52 weeks. In a third analysis the improvement of dyspnea (or shortness of breath), as measured by the Transition Dyspnea Index (TDI), was shown in COPD patients, compared to tiotropium, olodaterol and placebo.3